Literature DB >> 21138845

Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.

Christopher M Pirie1, Benjamin J Hackel, Michael G Rosenblum, K Dane Wittrup.   

Abstract

Gelonin-based immunotoxins vary widely in their cytotoxic potency as a function of antigen density, target cell internalization and trafficking kinetics, and conjugate properties. We have synthesized novel gelonin immunotoxins using two different binding scaffold types (single-chain antibody variable fragments and fibronectin domains) targeting two different tumor antigens (carcinoembryonic antigen and EGF receptor). Constructs were characterized using an antigen-negative cell line (HT-1080), cell lines positive for each antigen (HT-1080(CEA) for carcinoembryonic antigen and A431 for EGF receptor), and a cell line positive for both antigens (HT-29). Immunotoxins exhibited K(d) values between 8 and 15 nm and showed 20-2000-fold enhanced cytotoxicity compared with gelonin (IC(50) ∼ 0.25-30 nM versus 500 nM). Using quantitative fluorescence flow cytometry, we measured internalization of gelonin (via pinocytosis) and gelonin-based immunotoxins (via antigen-dependent, receptor-mediated endocytosis). Results were matched with cytotoxicity measurements made at equivalent concentration and exposures. Unexpectedly, when matched internalization and cytotoxicity data were combined, a conserved internalized cytotoxicity curve was generated that was common across experimental conditions. Considerable variations in antigen expression, trafficking kinetics, extracellular immunotoxin concentration, and exposure time were all found to collapse to a single potency curve on the basis of internalized immunotoxin. Fifty percent cytotoxicity occurred when ∼ 5 × 10(6) toxin molecules were internalized regardless of the mechanism of uptake. Cytotoxicity observed at a threshold internalization was consistent with the hypothesis that endosomal escape is a common, highly inefficient, rate-limiting step following internalization by any means tested. Methods designed to enhance endosomal escape might be utilized to improve the potency of gelonin-based immunotoxins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21138845      PMCID: PMC3039404          DOI: 10.1074/jbc.M110.186973

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Quantitative analysis of protein synthesis inhibition and recovery in CRM107 immunotoxin-treated HeLa cells.

Authors:  L A Wenning; P T Yazdi; R M Murphy
Journal:  Biotechnol Bioeng       Date:  1998-02-20       Impact factor: 4.530

2.  The fibronectin type III domain as a scaffold for novel binding proteins.

Authors:  A Koide; C W Bailey; X Huang; S Koide
Journal:  J Mol Biol       Date:  1998-12-11       Impact factor: 5.469

Review 3.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.

Authors:  S Hammarström
Journal:  Semin Cancer Biol       Date:  1999-04       Impact factor: 15.707

4.  Kinetics of cellular trafficking and cytotoxicity of 9.2.27-gelonin immunotoxins targeted against the high-molecular-weight melanoma-associated antigen.

Authors:  M C Chan; R M Murphy
Journal:  Cancer Immunol Immunother       Date:  1999-02       Impact factor: 6.968

5.  Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.

Authors:  L A Wenning; R M Murphy
Journal:  Biotechnol Bioeng       Date:  1999-03-05       Impact factor: 4.530

6.  Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.

Authors:  Françoise Kraeber-Bodéré; Caroline Rousseau; Caroline Bodet-Milin; Ludovic Ferrer; Alain Faivre-Chauvet; Loïc Campion; Jean-Philippe Vuillez; Anne Devillers; Chien-Hsing Chang; David M Goldenberg; Jean-François Chatal; Jacques Barbet
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

7.  Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.

Authors:  Surinder K Sharma; R Barbara Pedley; Jeetendra Bhatia; Geoffrey M Boxer; Ethaar El-Emir; Uzma Qureshi; Berend Tolner; Helen Lowe; N Paul Michael; Nigel Minton; Richard H J Begent; Kerry A Chester
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

8.  Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

Authors:  Robert J Kreitman; Raffit Hassan; David J Fitzgerald; Ira Pastan
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

9.  Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata.

Authors:  A M Di Massimo; M Di Loreto; A Pacilli; G Raucci; L D'Alatri; A Mele; A Bolognesi; L Polito; F Stirpe; R De Santis
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells.

Authors:  Y Akamatsu; J C Murphy; K F Nolan; P Thomas; R J Kreitman; S O Leung; R P Junghans
Journal:  Clin Cancer Res       Date:  1998-11       Impact factor: 13.801

View more
  30 in total

1.  Epidermal growth factor receptor downregulation by small heterodimeric binding proteins.

Authors:  Benjamin J Hackel; Jason R Neil; Forest M White; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2011-12-09       Impact factor: 1.650

2.  The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins.

Authors:  Alexander Weng; Mayank Thakur; Figen Beceren-Braun; Diana Bachran; Christopher Bachran; Sebastian B Riese; Kristina Jenett-Siems; Roger Gilabert-Oriol; Matthias F Melzig; Hendrik Fuchs
Journal:  Mol Oncol       Date:  2012-01-24       Impact factor: 6.603

Review 3.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors:  Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal:  Adv Drug Deliv Rev       Date:  2015-12-11       Impact factor: 15.470

Review 4.  Improved Protein Toxin Delivery Based on ATTEMPTS Systems.

Authors:  Yingzhi Chen; Meng Zhang; Kyoung Ah Min; Huiyuan Wang; Meong Cheol Shin; Feng Li; Victor C Yang; Yongzhuo Huang
Journal:  Curr Drug Targets       Date:  2018-02-19       Impact factor: 3.465

5.  Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin.

Authors:  Christopher M Pirie; David V Liu; K Dane Wittrup
Journal:  Mol Cancer Ther       Date:  2013-07-05       Impact factor: 6.261

6.  A mechanistic compartmental model for total antibody uptake in tumors.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  J Theor Biol       Date:  2012-09-06       Impact factor: 2.691

7.  Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.

Authors:  M B Berstad; L H Cheung; K Berg; Q Peng; A S V Fremstedal; S Patzke; M G Rosenblum; A Weyergang
Journal:  Oncogene       Date:  2015-02-16       Impact factor: 9.867

8.  In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.

Authors:  Xikun Zhou; Ji Qiu; Zhen Wang; Nongyu Huang; Xiaolei Li; Qian Li; Yinbing Zhang; Chengjian Zhao; Can Luo; Nannan Zhang; Xiu Teng; Zhongwen Chen; Xiao Liu; Xianlian Yu; Wenling Wu; Yu-quan Wei; Jiong Li
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-07       Impact factor: 4.553

9.  Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.

Authors:  Petra Kornberger; Arne Skerra
Journal:  MAbs       Date:  2013-12-09       Impact factor: 5.857

10.  Geometry and expression enhance enrichment of functional yeast-displayed ligands via cell panning.

Authors:  Lawrence A Stern; Ian A Schrack; Sadie M Johnson; Aakash Deshpande; Nathaniel R Bennett; Lauren A Harasymiw; Melissa K Gardner; Benjamin J Hackel
Journal:  Biotechnol Bioeng       Date:  2016-06-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.